Demonstrate the existence of neurodevelopmental alterations in organoids derived from samples of patients with bipolar disorder (BD) with a neurodevelopmental (ND) component, compared with patients with bipolar disorder (BD) without an ND component.

Inclusion Criteria:

• Presence of bipolar disorder according to DSM-5 criteria
• Able to freely give and sign consent
• Affiliated or beneficiary of a health insurance plan
• Previous participants in the NEMO study (2022-A00353-40)

For the "neurodevelopmental bipolar" (ND-BP) group: presence of a neurodevelopmental burden score in the top 5, as assessed in the NEMO project (NCT05674019).

For the "non-neurodevelopmental bipolar" group (TB): presence of a neurodevelopmental load score of 0, or in the lowest 5, as assessed in the NEMO project.

Exclusion Criteria:

• - Presence of a severe symptomatic or unstable physiological or medical condition (including pregnancy)
• History of psychiatric illness (stable or not), schizophrenia or any other pathology likely to interfere with bipolar disorder
• History of severe head trauma (GCS<8 at time of trauma)
• Presence of a neurological disorder affecting central nervous system function
• Presence of moderate to severe substance use disorders (>=4/11 as defined in DSM-5), with the exception of tobacco use disorders.
• The volunteer is under court protection or guardianship
• It proves impossible to give the volunteer informed information, or the volunteer refuses to sign the consent form.
• Insufficient command of the French language to complete evaluations